Skip to main content
. 2023 Oct 17;13:1289249. doi: 10.3389/fonc.2023.1289249

Table 3.

Percentage of patients reaching given PSA level in months following relugolix + SBRT treatment.

PSA (ng/ml) @ SBRT 1-4 (months) 5-8
≤1 37 (71.2%) 37 (94.9%) 14 (93.3%)
≤0.5 24 (46.2%) 34 (87.2%) 11 (73.3%)
≤0.2 7 (13.5%) 29 (74.4%) 7 (46.7%)
≤0.1 2 (3.8%) 24 (61.5%) 4 (26.7%)
<0.1 2 (3.8%) 19 (48.7%) 3 (20.0%)
N 52 39 15